Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 27, 2015 8:14 PM ET

Capital Markets

Company Overview of Truffle Capital

Company Overview

Truffle Capital is a venture capital and private equity firm specializing in startup, post start up, growth capital, investments in spins offs from initial round to the pre-exit round, LBOs, and PIPEs. The firm invests in information technology, energy, life sciences, telecommunication, electronics, and biotechnology and pharmaceuticals. In information technology, it focuses on mobile content and connectivity, Internet, technical software, IT security, VOIP, and security and technical software. Within energy, the firm typically invests in energy efficiency, energy management, new technologies for traditional energies, and renewable energy like solar, wind, wave power, tidal power, mini-hydro...

5, rue de la Baume

Paris,  75008

France

Founded in 2001

Phone:

33 1 82 28 46 00

Fax:

33 1 47 20 12 09

Key Executives for Truffle Capital

Chief Executive Officer, Co-Founder, General Partner, Founding Partner, and Managing Partner
Age: 57
Chairman, Co-Founder, and President
Age: 77
Co-Founder, Founding Partner, General Partner, and Managing Director
Age: 51
Chief Financial Officer and Chief Administrative Officer
Age: 61
Director of Operations and Risk Management, Support Team
Compensation as of Fiscal Year 2015.

Truffle Capital Key Developments

Truffle Capital Announces Creation of ABIVAX in Collaboration with the Cuban Center for Genetic Engineering and Biotechnology

Truffle Capital has announced the creation of ABIVAX in collaboration with the Cuban Center for Genetic Engineering and Biotechnology (CIGB). This is the first ever start-up launched on the basis of a Euro-Cuban R&D collaboration. The goal of ABIVAX is to become a global leader in therapeutic vaccines and antivirals, leveraging both its existing product pipelines and future acquisitions that are currently in negotiations. ABIVAX specializes in therapeutic vaccines and antivirals, combining the technologies and the product portfolios of three French biotech companies financed by Truffle Capital (Wittycell, Splicos and Zophis). An exclusive partnership agreement with the CIGB has been approved by the Cuban government and will further enrich the portfolio. The CIGB is a subsidiary under BioCubaFarma that specializes in the discovery, development and production of vaccines and antivirals. ABIVAX already possesses several key assets including complementary technology platforms, a high-value product portfolio and an experienced top management team.

Similar Private Companies By Industry

Company Name Region
QuantumWave Capital Europe
Empire Capital Partners SAS Europe
Barclays Bail SA Europe
Atina Conseil Europe
FVB Conseil Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
August 4, 2015
Momac B.V.
Private Placement
June 16, 2015
Actility S.A.
Private Placement
June 3, 2015
MyoPowers Medical Technologies SA
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Truffle Capital, please visit www.truffle.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.